Anteris Provides Promising Results from DurAVR™ THV First in Human Study
Tuesday, 11 June 2024, 07:16
Anteris Provides Data Update on DurAVR™ THV Study at New York Valves 2024
The latest data update from Anteris regarding the DurAVR™ transcatheter heart valve (THV) presented at the New York Valves 2024 conference shows significant progress and potentially positive outcomes.
Promising Results in First in Human Study
The study highlights important milestones achieved, indicating advancements in the field of transcatheter valve technology.
Anteris is demonstrating a commitment to innovation and excellence in cardiovascular healthcare, with the potential to redefine treatment standards.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.